Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 36-year-old Pakistani phenotypic female diagnosed with 46,XY 5-alpha-reductase deficiency, highlighting that such disorders of sexual development can manifest with symptoms like obesity, hirsutism, and amenorrhea later in life due to unique circumstances.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

This study investigated the effects of 5-alpha-reductase inhibitors on penile histomorphometry in both normotensive and hypertensive rats, reporting no significant changes between treated and untreated groups.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This study found that variations in sleep patterns, free testosterone, and 5-alpha-reductase type 1 activity are associated with changes in sebum excretion in women, which may contribute to variability in acne studies.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This study found that women taking 5α-reductase inhibitors (5aRI) for alopecia had a lower risk of breast cancer compared to those not using these medications, with no increased risk of developing ovarian or endometrial cancer.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This study found that finasteride treatment significantly reduced hirsutism scores in women with idiopathic hirsutism over 6 months and was well tolerated.

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.